🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to researchers.

An International Challenge

Cases of gonorrhoea are on the rise around the world, with data suggesting in excess of 82 million infections per year. Particularly high rates are observed in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the context of growing infection rates, escalating drug resistance and the highly restricted treatment choices at this time.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Secure Authorization

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists hope that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Outcomes and Global Access

According to data detailed in a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which involves an injection and a pill. The research included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to register and commercialise the drug in many developing nations.

Clinicians treating patients have expressed positive views. Having a single-dose, oral treatment like this is seen as a "game-changer" for managing the epidemic. This is viewed as crucial to reduce the burden of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea worldwide.